And now alley cat ALLR
$0.8351 +0.2352 (+39.21%)
As of Dec-05-20239:52:50 AM ET
Volume
34,886,118
10/90-day avg. vol.
220K / 431K
Day range $0.8050 - $1.11
52-week range $0.4500 - $1,890.0
The News
Allarity's Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic
BENZINGA
7:32 AM ET Dec-05-2023
Allarity Therapeutics, Inc. (ALLR.NaE) ("Allarity" or the "Company") , a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, today announced encouraging initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of its PARP inhibitor, stenoparib, in women with advanced ovarian cancer (AOC). Of the five evaluable patients included in the initial data analysis, one patient experienced a complete response and the other four demonstrated stable disease.
